INTERESTING EYE NEWS & CLINICAL PEARLS

A retrospective cohort study published in Translational Vision Science & Technology suggests that omega-3 fatty acid supplementation may significantly lower the risk of developing glaucoma in individuals with dry eye disease. Researchers analyzed data from 14,168 adult patients across a multinational database between 2013 and 2023. They compared a group prescribed omega-3 supplements against a matched control group over a five-year follow-up period. Key Findings Compared to the control group, patients who received omega-3 supplements experienced substantially lower risks across multiple conditions: Total Glaucoma: Risk reduced by 52% (HR: 0.48) Primary Open-Angle Glaucoma (POAG): Risk reduced by 55% (HR: 0.45) Normal-Tension Glaucoma (NTG): Risk reduced by 59% (HR: 0.41) Ocular Hypertension: Risk reduced by 43% (HR: 0.57) Primary Angle-Closure Glaucoma (PACG): Risk reduced by 55% (HR: 0.45) First-Line Glaucoma Medication Use: Risk reduced by 35% (HR: 0.65) Biological...

A 4.9-year longitudinal study published in the American Journal of Ophthalmology suggests that microvasculature dropout (MvD) detected via OCT angiography (OCT-A) serves as a critical prognostic marker for patients with preperimetric glaucoma (optic nerve damage without initial visual field loss). Key Study Findings Faster Vascular Decline: Eyes with baseline MvD experienced a significantly faster reduction in circumpapillary capillary density compared to those without MvD ( -0.88% per year vs. -0.23% per year ). Higher Conversion Rates: Over an average follow-up of 6.8 years, 62.5% of eyes with baseline MvD progressed to perimetric glaucoma (measurable visual field loss), compared to just 26.2% of eyes without it—a 2.5-fold higher risk. Baseline Vulnerability: At the start of the study, the MvD group already exhibited lower capillary density (45.6% vs. 47.7%) and thinner retinal nerve fiber layers (RNFL) than the control group. Clinical Takeaways Because capillary density loss...

  A retrospective cohort study analyzed electronic healthcare data from 70 US facilities (2005–2025) to evaluate how high-density lipoprotein cholesterol (HDL-C) levels impact the risk of age-related macular degeneration (AMD). Key Findings Higher Dry AMD Risk: High HDL-C levels were associated with a significantly increased risk of incident nonexudative (dry) AMD across all stages compared to low levels. Weaker Wet AMD Link: The association with exudative (wet) AMD was present but weaker and less consistent. Risk Breakdown (Hazard Ratios): Overall Dry AMD:Early Atrophic Stage: HR = 1.55 Intermediate Atrophic Stage: HR = 1.82 Advanced Atrophic Stage: HR = 1.85 Overall Wet AMD: HR = 1.37 Study Design & Methodology Researchers matched 186,532 subjects into high and low HDL-C groups based on demographics, medications, and comorbidities. The risk estimates remained directionally consistent and stable even after adjusting for these variables. The authors concluded that future st...

 Bausch + Lomb has introduced PreserVision AREDS3 , an over-the-counter oral supplement designed to reduce the risk of disease progression in patients with age-related macular degeneration (AMD). Key Features & Formulation Core Nutrients: Contains the complete, National Eye Institute-recommended AREDS2 formula to protect macular health by neutralizing free radicals (vitamins C and E, lutein, zeaxanthin, zinc, and copper). New B-Vitamin Complex: Adds thiamin, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, and vitamin B12 to promote healthy cellular eye function. Enhanced Absorption: Offers approximately twice the nutrient absorption of previous AREDS formulations. Scientific Backing The inclusion of B vitamins is supported by over two decades of research across more than 20 human studies (including the Women’s Antioxidant and Folic Acid Cardiovascular Study ), which tie specific B-vitamin supplementation to a reduced risk of AMD. Bausch + Lomb plans to con...

A retrospective cohort study published in Ophthalmology suggests that NSAIDs may reduce the risk of developing age-related macular degeneration (AMD) . Because inflammation plays a central role in both wet (exudative) and dry (non-exudative) AMD, researchers in Taiwan investigated whether the anti-inflammatory properties of these drugs offer a protective effect. Key Findings The study compared 634,794 patients prescribed NSAIDs against an equal number of non-users (both groups averaging roughly 60 years old) and found: Sustained Protection: NSAID users showed a reduced risk for AMD across all tracked time points, including at six months (HR: 0.31), one year (HR: 0.36), three years (HR: 0.42), and five years (HR: 0.48). Over the entire study duration, the overall hazard ratio was 0.58. Drug Types: The protective effect was observed both in patients prescribed aspirin (HR: 0.72) and those taking non-selective COX inhibitors other than aspirin (HR: 0.41). Subtypes & Comorbiditie...

A study from the ARVO 2026 meeting confirms that early intervention for geographic atrophy (GA) using pegcetacoplan (Syfovre) significantly improves long-term outcomes compared to delayed treatment. Key Study Findings Researchers analyzed 782 patients transitioning from the two-year OAKS/DERBY trials into the three-year GALE extension study. Superior Tissue Preservation: Patients who started treatment immediately (early group) preserved 3.87 mm² of retinal tissue over five years. Those who started two years late (delayed group) preserved only 1.93 mm² . Reduced Growth Rates: In nonsubfoveal GA, monthly injections reduced lesion growth by 33% compared to the sham group. Disease Delay: Continuous five-year therapy delayed the progression of nonsubfoveal GA by approximately 16.5 to 18.5 months . Safety Profile: The treatment remained well-tolerated over five years. Rare instances of retinal vasculitis occurred in fewer than 1 in 4,000 cases, consistent with earlier trial data. C...